Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Knuf

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Drug Research|November 20, 2018
Markus Knuf, Fred Zepp
Future Microbiology|May 17, 2019
Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidenceJamie Findlow, Markus Knuf
European Journal of Pediatrics|May 11, 2013
The burden of seasonal and pandemic influenza in infants and childrenBernhard R Ruf, Markus Knuf
Vaccine|May 10, 2011
Comparative effects of carrier proteins on vaccine-induced immune responseMarkus Knuf, Frank Kowalzik, Dorothee Kieninger
Deutsches Arzteblatt International|May 28, 2009
Varicella: efficacy of two-dose vaccination in childhoodPeter Wutzler, Markus Knuf, Johannes Liese
Vaccine|August 1, 2017
MMR and MMRV vaccinesFrank Kowalzik, Jörg Faber, Markus Knuf
Deutsches Arzteblatt International|December 10, 2013
Targeted vaccine selection in influenza vaccinationPeter Wutzler, Roland Hardt, Markus Knuf, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|February 10, 2023
[Delayed-Interval Delivery of an Extremely Preterm Twin after Abort of the First Twin and Emergency Total Cervical Occlusion at 19+1 Weeks of Gestation - a Case Report]Matthias Kögel, Matthias Werner, Markus Knuf, et al.
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
A combination vaccine against measles, mumps, rubella and varicellaMarkus Knuf, Jörg Faber, Immanuel Barth, et al.
Vaccine|December 14, 2011
The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studiesChristopher S Ambrose, Xionghua Wu, Markus Knuf, et al.
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Drug Research|November 20, 2018
Markus Knuf, Fred Zepp
Future Microbiology|May 17, 2019
Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidenceJamie Findlow, Markus Knuf
European Journal of Pediatrics|May 11, 2013
The burden of seasonal and pandemic influenza in infants and childrenBernhard R Ruf, Markus Knuf
Vaccine|May 10, 2011
Comparative effects of carrier proteins on vaccine-induced immune responseMarkus Knuf, Frank Kowalzik, Dorothee Kieninger
Deutsches Arzteblatt International|May 28, 2009
Varicella: efficacy of two-dose vaccination in childhoodPeter Wutzler, Markus Knuf, Johannes Liese
Vaccine|August 1, 2017
MMR and MMRV vaccinesFrank Kowalzik, Jörg Faber, Markus Knuf
Deutsches Arzteblatt International|December 10, 2013
Targeted vaccine selection in influenza vaccinationPeter Wutzler, Roland Hardt, Markus Knuf, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|February 10, 2023
[Delayed-Interval Delivery of an Extremely Preterm Twin after Abort of the First Twin and Emergency Total Cervical Occlusion at 19+1 Weeks of Gestation - a Case Report]Matthias Kögel, Matthias Werner, Markus Knuf, et al.
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
A combination vaccine against measles, mumps, rubella and varicellaMarkus Knuf, Jörg Faber, Immanuel Barth, et al.
Vaccine|December 14, 2011
The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studiesChristopher S Ambrose, Xionghua Wu, Markus Knuf, et al.
Pageof 12